TransMedics Group (TMDX)
(Delayed Data from NSDQ)
$142.19 USD
-1.74 (-1.21%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $142.07 -0.12 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TMDX 142.19 -1.74(-1.21%)
Will TMDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TMDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TMDX
TransMedics (TMDX) Just Reclaimed the 20-Day Moving Average
Are You Looking for a Top Momentum Pick? Why TransMedics (TMDX) is a Great Choice
TMDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Trending Stock TransMedics Group, Inc. (TMDX) a Buy Now?
Will TransMedics (TMDX) Gain on Rising Earnings Estimates?
Illumina (ILMN) Q1 Earnings Beat, Adjusted Operating Loss Widens
Other News for TMDX
What's Driving Tandem Diabetes Care Inc's Surprising 15% Stock Rally?
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Analysts Are Bullish on Top Healthcare Stocks: Ocular Therapeutix (OCUL), TransMedics Group (TMDX)
Critical Insights From TransMedics Gr Analyst Ratings: What You Need To Know
The 3 Best Medical Device Stocks to Buy in June 2024